Amalgent Therapeutics, LLC

Greenville, NC · Founded 2020 · CIK 0001924038 · Biotech · Private

Fixed-dose combination therapeutic combining pramipexole and morphine to reduce opioid doses needed for pain relief

amalgent.com →
Grants
$5.4M
3 awards
Sector median: 1
Raised
$200K
1 Form D · Apr 2022
54 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$200,000
Federal grantDepartment of Health and Human Services · Phase II · Development of an Opioid Sparing Therapeutic to Minimize Opioid Use Disorderand Tolerance in the Treatment of Pain$2,579,875
Federal grantDepartment of Health and Human Services · Phase II · Development of an Opioid Sparing Therapeutic to Minimize Opioid Use Disorderand Tolerance in the Treatment of Pain$2,579,875
Federal grantDepartment of Health and Human Services · Phase I · Mechanism and Efficacy of a Novel Opioid Adjuvant$220,668
Federal grant · SBIR/STTRForm D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2632Reven Holdings Inc—$200K
2633NonExomics, Inc.—$200K
2634FruitVaccine Incorporation——
2635Amalgent Therapeutics, LLC—$200K
2636Rapport Therapeutics——
2637COSMICA Inc.—$200K
2638Ayala Pharmaceuticals, Inc.—$45M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 2 related persons
  • Malcolm MeynDirector · Executive Officer
  • Sam TetlowDirector

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.